SecBot SecBot
PRESS-RELEASE ·Filed Apr 14, 2026

PRAX

Praxis Precision Medicines, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The lack of an advisory committee meeting reduces regulatory risk and increases approval probability ahead of the PDUFA date. Traders should monitor for any FDA updates and position ahead of the January 2027 decision, especially given the drug's Breakthrough Therapy status and strong Phase 3 data.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$343.60
T+0 close · Apr 14, 2026 · via day close
Latest settled
−3.05%
T+60 · $333.12
Vs SPY
−11.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $343.60entry
  2. T+1 · 7mo ago −1.07%α −1.84% · $339.93
  3. T+5 · 7mo ago −0.80%α −2.20% · $340.84
  4. T+20 · 6mo ago −3.43%α −9.73% · $331.81
  5. T+60 · 4mo ago −3.05%α −11.57% · $333.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl to treat essential tremor, with a PDUFA target action date of January 29, 2027. The FDA does not plan to hold an advisory committee meeting, accelerating the review timeline.

Key Facts

  • FDA accepted NDA for ulixacaltamide HCl for essential tremor with PDUFA date of January 29, 2027
  • No advisory committee meeting planned, indicating streamlined review process
  • NDA supported by positive Phase 3 Essential3 trial results showing statistically and clinically significant efficacy
  • Ulixacaltamide received Breakthrough Therapy Designation in December 2025
  • Drug was generally well tolerated with no drug-related serious adverse events

Financial Impact

Potential first-in-class therapy for essential tremor, a market with high unmet need; commercial launch preparation underway

revenuemarketCapvaluation

Risk Factors

  • Regulatory delay or rejection despite PDUFA date
  • Commercial execution risk post-approval
  • Competition from emerging therapies in CNS space

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3273225

Track record

16 reports on PRAX

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
  2. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  5. Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
  7. Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
  9. Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
  10. May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 14, 2026